Gyrase inhibitors and uses thereof
AssigneeVertex Pharmaceuticals Incorporated
InventorsAnne-Laure Grillot, Paul Charifson, Dean Stamos, Yusheng Liao, Michael Badia, Martin Trudeau
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
Claims26
A compound of formula IIa or IIb:
- or a pharmaceutically acceptable salt thereof, wherein:
- W is nitrogen or CRa;
- Ra is selected from hydrogen, halogen, —CF3, R7, —OR7, or —N(R7)2;
- R1 is an aryl or heteroaryl ring, wherein said ring is optionally substituted by up to four R9;
- wherein an R9 substituent in the ortho-position of R1 taken together with R2 may form a fused, unsaturated or partially unsaturated, optionally substituted 5-8 membered ring having 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- R2 and R3 are each independently selected from R6, halogen, CN, SR6, OR6, N(R6)2, NRCO2R6, NRCON(R6)2, CON(R6)2, NRCOR6, NRN(R6)2, COR6, CO2R6, COCOR6, SO2R6, SO2N(R6)2, or NRSO2R6;
- or R2 and R3 are taken together to form a fused, unsaturated or partially unsaturated, optionally substituted 5-8 membered ring containing 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- R4 is selected from R6, CON(R6), COR6, CO2R6, COCOR6, SO2R6, SO2N(R6)2, or (CH2)yR2;
- y is 1-6;
- Ar is a five membered heteroaryl, heterocyclyl, or carbocyclyl ring, wherein said ring is optionally substituted by up to three substituents selected from oxo, halogen, CN, NO2, R8, OR8, NHR8, NHCOR8, NHCONHR8, COR8, CONHR8, SO2R8, NHSO2NHR8 or SO2NHR8;
- each R6 is independently selected from R7 or an optionally substituted group selected from alkoxy, hydroxyalkyl, heterocyclyl, heterocyclcylalkyl, aryl, aralkyl, aralkoxy, aryloxyalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, or heteroarayloxyalkyl;
- each R7 is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons, or two R7 on the same nitrogen taken together with the nitrogen optionally form a four to six member, saturated or unsaturated heterocyclic ring having one to three heteroatoms;
- R8 is a C1-C4 aliphatic group, wherein two R8 on adjacent positions of Ar, or an aryl or heteroaryl ring, may be taken together with their intervening atoms to form a three to six membered fused ring;
- each R9 is independently selected from oxo, halogen, CN, NO2, Tn(haloalkyl), R6, SR6, OR6, OR8, N(R6)2, CON(R6)2, CON(R)COR6, COR6, CO2R6, CO2N(R6)2, COCOR6, SO2R6, SO2N(R6)2, N(R)TnCO2R6, N(R)TnCON(R6)2, N(R)TnN(R6)2, N(R)TnNRCO2R6, N(R)TnNRCON(R6)2, N(R)TnCOR6, N(R)TNRCOR6, N(R)TnSO2N(R6)2, N(R)TnSO2R6, TnPO(OR7)2, TnOPO(OR7)2, TnSP(OR7)2, TnPO(OR7)2, or TnNPO(OR7)2;
- each Q is an independently selected C1-C3 branched or straight alkyl;
- T is selected from —Q— or —Qm—CH(Qm—R2)—;
- and
- each m and n are independently selected from zero or one.
A compound of formula IIIa or IIIb:
- or a pharmaceutically acceptable salt thereof, wherein:
- W is nitrogen or CRa;
- Ra is selected from hydrogen, halogen, —CF3, R7, —OR7, or —N(R7)2;
- Ring A is optionally substituted with up to three R9;
- wherein when an R9 substituent is in the ortho-position of Ring A, said R9 substituent may be taken together with R2 to form an optionally substituted 5-7 membered ring containing 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- R2 and R3 are each independently selected from R6, halogen, CN, SR6, OR6, N(R6)2, NRCO2R6, NRCON(R6)2, CON(R6)2, NRCOR6, NRN(R6)2, COR6, CO2R6, SO2R6, SO2N(R6)2, or NRSO2R6;
- or R2 and R3 are taken together to form a fused, unsaturated or partially unsaturated, optionally substituted 5-8 membered ring containing 0-2 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- R4 is selected from R6, CON(R6), COR6, CO2R6, COCOR6, SO2R6, SO2N(R6)2, or(CH2)yR2;
- y is 1-6;
- R5 is selected from R7, Ar, COAr, CON(R7)Ar, (CH2)yCO2R, (CH2)yN(R7)2, C(═NR10)—N(R7)2, C(═NR10)—NRCOR, C(═S)—N(R7)2, CON(R7)2, COR, SO2R, or SO2N(R7)2;
- Ar is a five membered heteroaryl, heterocyclyl, or carbocyclyl ring, wherein said ring is optionally substituted by up to three substituents selected from oxo, halogen, CN, NO2, R8, OR8, NHR8, NHCOR8, NHCONHR8, COR8, CONHR8, SO2R8, NHSO2NHR8 or SO2NHR8;
- each R6 is independently selected from R7 or an optionally substituted group selected from alkoxy, hydroxyalkyl, heterocyclyl, heterocyclcylalkyl, aryl, aralkyl, aralkoxy, aryloxyalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, or heteroarayloxyalkyl;
- each R7 is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons, or two R7 on the same nitrogen taken together with the nitrogen optionally form a four to six member, saturated or unsaturated heterocyclic ring having one to three heteroatoms;
- R8 is a C1-C4 aliphatic group, wherein two R8 on adjacent positions of Ar, or an aryl or heteroaryl ring, may be taken together with their intervening atoms to form a three to six membered fused ring;
- each R9 is independently selected from oxo, halogen, CN, NO2, Tn(haloalkyl), R6, SR6, OR6, OR8, N(R6)2, CON(R6)2, CON(R)COR6, COR6, CO2R6, CO2N(R6)2, COCOR6, SO2R6, SO2N(R6)2, N(R)TnCO2R6, N(R)TnCON(R6)2, N(R)TnN(R6)2, N(R)TnNRCO2R6, N(R)TnNRCON(R6)2, N(R)TnCOR6, N(R)TnNRCOR6, N(R)TnSO2N(R6)2, N(R)TnSO2R6, TnPO(OR7)2, TnOPO(OR7)2, TnSP(OR7)2, TnPO(OR7)2, or TnNPO(OR7)2;
- each Q is an independently selected C1-C3 branched or straight alkyl;
- T is selected from —Q— or —Qm—CH(Qm—R2)—;
- each m and n are independently selected from zero or one;
- and R10 is selected from R7 or Ar.
A compound selected from the group consisting of:
- No. Ia- Structure 20 25 28 29 33 35 38 40 — — 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 68 — — 83 84 89 92 98 99 100 102 103 104 105 106 107 108 109 110 111 112 113 116 117 118 119 120 121 — — 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 and 200
A compound selected from the group consisting of:
- No. Ib- Structure 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24 25 26 27 and 28
Dependencies are inferred from the claim text.